Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191049 | 1.00 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4195214 | 1.00 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4195211 | 1.00 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4191039 | 1.00 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4191043 | 1.00 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4189471 | 0.91 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4201856 | 0.91 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4194724 | 0.91 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4201849 | 0.91 | SLC6A3 (0.31) | SLC6A3 | |
| SCHEMBL4194720 | 0.91 | SLC6A3 (0.31) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | KLAR ULRICH | 2009-01-15 | — | — | US | disclosed |
| US-7407975-B2 | Epothilone derivatives, method for producing same and their pharmaceutical use | BAYER SCHERING PHARMA AG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | US | disclosed |
| US-7001916-B1 | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals | SCHERING, AG (DE) | 2006-02-21 | — | — | US | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | PTGIS, PTGES, PTGES2 | SLC6A3 4561/4885 |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | SLC6A3 4569/4885 |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | TUBB4A, TUBA1B, TUBB | SLC6A3 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.